sm-346 and Cardiovascular-Diseases

Afobazole was administered to 32 patients, aged 18-60 years, with cardio-vascular diseases and neurotic stress-related psychopathologies and somatoform disorders (ICD-10 F40-F45). The drug was assigned in dosages from 30 to 60 mg daily (mean 50 mg) during 6 weeks, along with basic somatotropic therapy. Twenty-nine patients completed the course. Therapeutic efficacy was assessed by the Hamilton anxiety scale (HAM-A) and a subscale of the Global Clinical Impression scale (CGI). The total number of responders was 21 (70%). The improvement began from the 1st week of the treatment and increased to the 42nd day. At the same time, intensity of mental disorders (phobic, somatisized, anxiety-depressive) gradually decreased up to complete reduction. Afobazole was well-tolerated by patients.

Topics: Adolescent; Adult; Anxiety Disorders; Benzimidazoles; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Treatment Outcome